Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

T, Kojima; MA, Shah; K, Muro; E, Francois; A, Adenis; CH, Hsu; T, Doi; T, Moriwaki; SB, Kim; SH, Lee; J, Bennouna; K, Kato; L, Shen; P, Enzinger; SK, Qin; P, Ferreira; J, Chen; G, Girotto; la Fouchardiere C, de; H, Senellart; R, Al-Rajabi; F, Lordick; R, Wang; S, Suryawanshi; P, Bhagia; SP, Kang; JP, Metges

doi:10.1200/jco.20.01888

Public

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Shared by NobleBlocks on Oct 7, 2020 • 12:00 AM UTC

Authors:

Kojima T

Shah MA

Muro K

Abstract

Purpose Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy.Patients and methods In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metastatic squamous cell carcinoma or adenocarcinoma of t...

Discussions